<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A role for B-cell-receptor (BCR) signalling in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> has been inferred by studying immunoglobulin genes in human <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is needed </plain></SENT>
<SENT sid="1" pm="."><plain>Here we describe a form of '<z:hpo ids='HP_0011010'>chronic</z:hpo> active' BCR signalling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The signalling adaptor CARD11 is required for constitutive NF-kappaB pathway activity and survival in <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Roughly 10% of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> have mutant CARD11 isoforms that activate NF-kappaB, but the mechanism that engages <z:mp ids='MP_0002169'>wild-type</z:mp> CARD11 in other <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> was unknown </plain></SENT>
<SENT sid="4" pm="."><plain>An <z:chebi fb="40" ids="33697">RNA</z:chebi> interference genetic screen revealed that a BCR signalling component, Bruton's tyrosine kinase, is essential for the survival of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> with <z:mp ids='MP_0002169'>wild-type</z:mp> CARD11 </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, knockdown of proximal BCR subunits (IgM, Ig-kappa, CD79A and CD79B) killed <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> with <z:mp ids='MP_0002169'>wild-type</z:mp> CARD11 but not other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The BCRs in these <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e> formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated <z:mpath ids='MPATH_458'>normal</z:mpath> B cells </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutations</z:hpo> affecting the immunoreceptor tyrosine-based activation motif (ITAM) signalling modules of CD79B and CD79A were detected frequently in <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e> biopsy samples but rarely in other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> and never in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or mucosa-associated lymphoid tissue <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In 18% of <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCLs</z:e>, one functionally critical residue of CD79B, the first ITAM tyrosine, was mutated </plain></SENT>
<SENT sid="9" pm="."><plain>These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signalling </plain></SENT>
<SENT sid="10" pm="."><plain>These findings establish <z:hpo ids='HP_0011010'>chronic</z:hpo> active BCR signalling as a new pathogenetic mechanism in <z:e sem="disease" ids="C1333296" disease_type="Neoplastic Process" abbrv="">ABC DLBCL</z:e>, suggesting several therapeutic strategies </plain></SENT>
</text></document>